The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development

January 14, 2020

The cover for issue 2 of Oncotarget features Figure 5, "MASPIN can prevent the formation of UPA - UPA-receptor complex by a single step, and thus decrease the possibility of the abnormal degradation of the ECM, the development metastasis and angiogenesis," by Fodor, et al.

In the present study, the research team investigated AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory factors related to angiogenesis and metastasis in LHRH receptor-positive OCM3 cells.

Their results show that AEZS-108 upregulates the expression of MASPIN/SERPINB5 tumor suppressor gene, which is downregulated in the normal uvea and UM specimens independently from the LHRH receptor-ligand interaction.

In order to investigate the mechanism of the induction of MASPIN by AEZS-108, OCM3 cells were treated with free DOX, D-Lys6 LHRH analog, or AEZS-108.

Dr. Gabor Halmos from the University of Debrecen, Department of Biopharmacy, in Debrece, Hungary as well as the Veterans Affairs Medical Center, Endocrine, Polypeptide and Cancer Institute, in Miami, FL, USA said, "Although uveal melanoma (UM) is a rare disease, it is the most prevalent lethal ophthalmological tumor."

The discovery of specific receptors for peptide hormones on cancer cells has led to the development of cytotoxic or radiolabeled hormone analogs that are appropriate for tumor localization and targeted therapy.

AEZS-108 guides the chemotherapeutic agent specifically to those tumors that express LHRH-receptors, which could result in targeted cytotoxicity and less damage to healthy tissues.

The authors reported that previously OCM3 UM cell line expresses the receptor of LHRH localized on the cell membrane and in the cytoplasm, rendering them susceptible to AEZS-108 uptake and the detection of the LHRH receptor in OCM3 cells has led to the use of AEZS-108 for targeted therapy of the tumor.

Moreover, that the OCM3 UM cell line expresses the LHRH receptor and LHRH rendering them susceptible to AEZS-108 uptake.

The Halmos Research Team concluded, "In summary, our data confirmed previous results showing LHRH receptor expression in OCM3 cells, a UM in vitro model. Furthermore, we report for the first time that AEZS-108 causes changes in the expression of genes that are involved in angiogenesis and ECM degradation and which might inhibit cell proliferation and induce apoptosis in OCM3 cells.

These findings suggest that AEZS-108 plays a pivotal role in the regulation of angiogenesis and tumor suppression. Taken together, targeted cytotoxic LHRH analogs, such as AEZS-108, might serve as an effective treatment for patients with LHRH receptor-positive uveal melanoma."

Impact Journals LLC

Related Angiogenesis Articles from Brightsurf:

Oncotarget: miR-151a enhances Slug dependent angiogenesis
Volume 11, Issue 23 of @Oncotarget reported that the authors have previously established that mi R-151a functions as an onco-mi R in non-small cell lung cancer cells by inducing partial EMT and enhancing tumor growth.

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development
In the present study, the research team investigated AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory factors related to angiogenesis and metastasis in LHRH receptor-positive OCM3 cells.

A newly identified mechanism can be targeted to boost angiogenesis
Scientists of the National Center for Cardiovascular Research (CNIC) have discovered a cellular and molecular mechanism that can be exploited to induce productive and sustained angiogenesis in tissues that have become ischemic due to reduced blood supply.

Blood runs deep: Lab blood vessel model sheds light on angiogenesis
Researchers at the University of Tokyo and at CNRS in France revealed the importance of the molecule EGFL7 for angiogenesis and endothelial integrity using an artificially created blood vessel model called a microvessel-on-a-chip.

FDA-approved drug may block resistance to anti-angiogenesis therapy
A Massachusetts General Hospital research team has identified a potential strategy for improving the efficacy of angiogenesis inhibitors, drugs that help fight cancer by blocking the formation of new blood vessels.

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina--the sensory tissue at the back of the eye--using gene-editing techniques with CRISPR-Cas9.

NYU Tandon's 3-D microscopic voyage at SXSW spotlights angiogenesis research
High school seniors accepted to NYU Tandon School of Engineering will receive 3-D cardboard viewers that will take them on a journey to a microscopic, intracellular world -- a virtual reality (VR) game environment where they can watch cells communicate using chemical signals.

Heart bypass without surgery? -- AGGF1 induces therapeutic angiogenesis through autophagy
Coronary artery disease, the number one killer world-wide, restricts and ultimately blocks blood vessels, cutting off oxygen supply to the heart.

Going to 'Wars' against cancer and heart disease
Wars2 was discovered to be involved in angiogenesis -- blood vessel formation, which is important in ensuring that all parts of the body get nutrients to sustain life.

Targeting 2 angiogenesis pathways could improve results of glioblastoma treatment
Two companion papers from Massachusetts General Hospital research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably developed by the devastating brain tumor glioblastoma.

Read More: Angiogenesis News and Angiogenesis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.